Влияние фактора пигментного эпителия (PEDF) на состояние сетчатки, процессы неоваскуляризации в эксперименте
Диссертация
Таким образом, на основании сравнительного морфометрического анализа установлено, что при интравитреальном введении PEDF или Авастина в опытные глаза животным с экспериментальной моделью происходит статистически достоверное снижение средней площади васкуляризации в пределах поверхностного ретинального слоя, как по сравнению с контрольными глазами в этих группах (р<0,001), так и с группой животных… Читать ещё >
Список литературы
- Богданович В.Л. Сахарный диабет.// Нижний Новгород 1997.-С.56−70.
- Беляева М.И. Профилактическая лазертерапия при диабетической ретинопатии // Тез. докл. У Всесоюзного съезда офтальмологов.- М., 1979.-Т.З.- С. 112−114.
- Габель В.П. Фотодинамическая терапия: показания и результаты.// Тез. докл. Первый Всероссийский семинар «круглый стол».- Ростов-на-Дону, 2004.- С. 104−107.
- Глинчук Я.И. Витрэктомия как метод профилактики и лечения ряда заболеваний стекловидного тела и сетчатки //Сб. научн.стат.:Трансцилиарная хирургия хрусталика и стекловидного тела.- М., 1982.- С.102−107.
- Глинчук Я.И. Хирургическое лечение гемофтальмов и помутнений стекловидного тела методом закрытой витрэктомии. // Автореф. дисс. канд. мед. наук.- М., 1975. 146 с.
- Глинчук Я.И., Югай А. Г., Деев, Л.А. Результаты витрэктомии и лазерных вмешательств при осложненных формах пролиферативной диабетической ретинопатии //Материалы Болгаро-советской конференции «Диабет и око». -Албена, Болгария, 1988. С.39−40.
- Григорян Э.Н., Иванова И. П., Поплинская В. А. Обнаружение новых, внутренних источников регенерации нейральной сетчатки после ее отслойки у тритонов. I. Морфологическое и количественное исследования // Изв. АН. Сер. биол. 1996. — № 3. — С. 319−332.
- Григорян Э.Н., Поплинская В. А. Обнаружение внутренних источников регенерации нейральной сетчатки после ее отслойки у тритонов. II. Радиоавтографическое исследование // Изв. АН. Сер. биол. 1999. — № 5. — С. 583−591.
- Ефимов А.С. //Проблемы эндокринологии.- 1985.- № 5.- С.55−59.
- Иванишко Ю.А. «Классические» субфовеолярные неоваскулярные мембраны: возможности и перспективы лечения.// Тез. докл. Первый Всероссийский семинар круглый стол".- Ростов-на-Дону, 2004 — С. 96−103.
- Иванишко Ю.А. Лазерные методы лечения заболеваний макулярной области сетчатки.// Автореф. дисс. д.м.н. Ростов-на-Дону, 1992 — 450 с.
- Измайлов А.С., Балашевич Л. И. Хориоидальная неоваскуляризация (диагностика и лечение).// Учебное пособие СПб, 2001. — С. 9−13.
- Кацнельсон Л.А., Форофонова Т. И., Бунин А. Я. Сосудистые заболевания глаза.//М. Медицина, 1990. С.182−196.
- Кашинцева Л.Т. Офтальмоскопические изменения глазного дна у больных сахарным диабетом и их классификация. //Офтальмологический журнал.- 1980. -№ i. С.108−112.
- Краснов М.М., Акопян B.C. Достижения лазеротерапии на современном этапе развития офтальмологии.// Сб. научн. трудов: Лазерные методы лечения в офтальмологии /Под ред. Краснова М.М.- М., 1984.- С.3−17
- Краснов М.М., Архангельский В. В. Возможности применения витреофага в офтальмохирургии. //Вестник офтальмологии.- 1976. № 4.-С.48−53.
- Либман Е.С., Шахова Е. В. Состояние и динамика слепоты и инвалидности вследствие патологии органа зрения в России.// Матер. VII съезда офтальмологов России М., 2000. — С.209−214.
- Лазеры в офтальмологии /Под ред. Сапрыкина П.И.- Изд. Саратовского университета, 1982.- С. 206−210.
- Мазунин И.Ю. Транспупиллярная термотерапия различных видов субретинальных неоваскулярных мембран. // Тезисы докладов. Первый Всероссийский семинар-«круглый стол».- Ростов-на-Дону, 2004. С. 115— 118.
- Марголис М. Г. Малькович В.К. О дифференциально-диагностических признаках изменений глазного дна при сахарном диабете. //Вестник офтальмологии.- 1980. № 2.- С.31−33.
- Мухина М.А., Сотникова Е. В., Кутенова О. М. Социальная значимость и актуальность проблемы лечения макулодистрофии.// Матер. VTI съезда офтальмологов России. М., 2000. — С.220−225.
- Родин А.С., Болынунов А. В. Результаты фотодинамической терапии при субфовеолярных субретинальных неоваскулярных мембранах. // Вестник офтальмологии.-2003 № 2 — С. 11−13.
- Сапрыкин П.И., Симонова К. К., Беляева М. И. Применение аргонового лазера в лечении диабетической ретинопатии (Предварительное сообщение). //Вестник офтальмологии.- 1974. № 2.- С.78−81.
- Семенов А.Д., Плюхова О. А., Ромашенков Ф. А. Ангиографическая характеристика и лазерное лечение ранних форм диабетичекой ретинопатии //Патология сосудистой и сетчатой оболочек глаза: Тез.докл.- Кишинев, 1981.- С.125−126.
- Симонова К.К. Аргоновый лазер в лечении диабетической ретинопатии. // Офтальмоэндокринология: Сб.научн.трудов.- М., 1978.-С.156−157.
- Федоров С.Н., Глинчук Я. И., Захаров в.Д., Зуев В. К. Удаление и замена стекловидного тела физиологическим раствором при помощи витреотома. //Вестник офтальмологии.- 1974. № 3.- С.24−27.
- Федоров С.Н., Глинчук Я. И., Семенов А. Д. Витрэктомия и лазер в лечении тяжелых форм диабетической ретинопатии. //Офтальмоэндокринология: Сб.науч.трудов.- М., 1978, — С. 165−167.
- Шульпина Н.Б., Алиева З. А., Нудьга Л. И. Заболевания органа зрения при сахарном диабете. //Терапевтическая офтальмология /Под ред. Краснова М. М., Шульпиной Н.Б.- М., 1985.- С.510−536.
- Adamis А.Р., Miller J.W., Bernal М.Т., D’Amico D.J., Folkman J., Yeo Т.К., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. // Am. J. Ophthalmol. 1994. — Vol. 118.-P.445−450.
- Aiello L.P., Avery R.L., Arrigg P.G. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. // N. Eng. J. Med. 1994. — Vol. 331. — P. 1480−1487.
- Alon Т., Hemo I., Itin A. et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. //Nat. Med. 1995. — Vol. 1. — P.1024−1028.
- Apte R., Barreiro R.A., Duh E., Volpert O., Ferguson T.A. Stimulation of neovascularization by the anti-angiogenic factor PEDF. // Invest. Ophthalmol. Vis. Sci. 2004. — Vol. 45 (12). — P.4491−4497.
- Araki Т., Tanawaki Т., Becerra S., Chader G., Schwartz J.
- Pigment epithelium-derived factor (PEDF) differentially protects immature but not mature cerebellar granule cells against apoptotic cell death. // J. Neurosci. Res. 1998.-Vol. 53.-P.7−15.
- Ashton N. Retinal vascularisation in health and disease. // Am. J. Ophthalmol. 1957. — Vol. 44. — P.7−17.
- Avery R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. // Retina. 2006. — Vol. 26. — P.352−354.
- Avery R.L., Pearlman J., Pieramici D.J. et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.// Ophthalmology. -2006.-Vol. 113(10).-P.1695−1715.
- Avery R.L., Pieramici D.J., Rabena M.D. et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. // Ophthalmology. -2006. Vol. 113. — P.363−372.
- Barakova M., Khobelich, Tanev V. Area coagulated retina depending on the extent of the retinal ishemia in eyes with proliferative diabetic retinopathy. //Acta. Medica Bulgaria. 1994. — Vol. XII. — P.29−34.
- Barnstable С .J., Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. // Prog. Retin. Eye Res. 2004. — Vol. 23(5). — P.561−77.
- Barondes M.J., Pagliarini S., Chisholm I.H. et al. Controlled trial of laser photocoagulation of pigment epithelial detachments in the elderly: 4 year review. // Br. J. Opthalmol. 1992. — Vol. 76. — P.5−7.
- Bashshur Z.F., Bazarbachi A., Schakal A. et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. // Am. J. Ophthalmol. 2006. — Vol. 142. — P. 1−9.
- Becerra S.P. Adv. Structure-function studies on PEDF: A noninhibitory serpin with neurotrophic activity. // Exp. Med. Biol. 1997. — Vol. 425. — P.223−237.
- Becerra S.P., Fariss R.N., Wu Y.Q., Montuenga L.M. et al. Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. // Exp. Eye Res. -2004. Vol. 78(2). — P.223−234.
- Berkow J.W., Orth D.H., Kelley J.S. Fluorescein Angiography: Techniques and Interrelation (Monograph N5). 1991. — P.65−93.
- Bienkowski J. An overview of the progression of diabetic retinopathy with treatment recommendations. //Nurse Pract. 1994. — Vol. 19(7). -P.50−58.
- Bilak M., Corse A., Lehar M., Tombran-Tink J., et al. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. // J. Neuropath. Exp. Neurol. 1999. — Vol. 58. — P.719−725.
- Boyd S., Zachary I., Chakravarthy U. et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. // Arch. Ophthalmol. 2002. — Vol. 120. — P.1644−1650.
- Bressler N. M, Bressler S.B. Photodynamic Therapy with Verteporfin (Visudyne): Impact on Ophthalmology and Visual Sciences. // Invest. Ophthalmol. Vis. Sci. 2000. — Vol. 41. — P.624 -628.
- Browning J., Wylie C., Gole G. Quantification of oxygen-induced retinopathy in mouse. // Invest. Ophthalmol. Vis. Sci. 1997. — Vol. 38. — P. 11 681 174.
- Cao W., Tombran-Tink J., Chen W., McGinnis J. Pigment epithelium-derived factor protects retinal neurons against hydrogen peroxide-induced ceel death. // Invest. Ophthalmol. Vis. Sci. 1999. — Vol. 40. -P.160−165.
- Cao W., Tombran-Tink J., Elias R., Sezate S., Mrazek D., McGinnis J.F. In vivo protection of photoreceptors from light damage by pigment epitheliumderived factor. // Invest. Ophthalmol. Vis. Sci. 2001. 1. Vol. 42(7). -P.1646−1652.
- Cayouette M., Smith S.B., Becerra S.P., Gravel C. Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. // Neurobiol. Dis. 1999. — Vol. 6(6). — P.523−532.
- Chalam К. V., Gupta S. et al. // 24-th Annual ASRS Meeting/ 6-th Annual EVRS Meeting. Cannes, 2006. — P. 173−174.
- Chen C.Y., Wong T.Y., Heriot W.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. // Am. J. Ophthalmol. 2007. — Vol. 143(3). -P.510−512.
- Chun D.W., Heier J.S. et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. // Ophthalmology. 2006. — Vol. 113(10). — P.1706−1712.
- Ciulla T.A., Danis R.P., Criswell M., Pratt L.M. Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. // Expert Open Investing Drugs. 1999. — Vol. 8(12). -P.2173−2182.
- Corcostequi B. Clinical experience with the diode laser in the management of diabetic retinopathy. // Symposium: New dimensions in retina. Chicago, Illinois. — 1993.-P.323−325.
- Costa R.A., Jorge R., Calucci D. et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. // Invest. Ophthalmol. Vis. Sci. 2006. — Vol. 47. — P.4569−4578.
- D’Amore P.A. Mechanisms of retinal and choroidal neovascularization. // Invest. Ophthalmol. Vis. Sci. 1994. — Vol. 35. -P.3974−3979.
- Davidorf F.H., Mouser J.G., Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. // Retina. 2006. — Vol. 26. -P.354−356.
- Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. // Science. 1999. -Vol. 285. -P.245−248.
- DRVSRG. Early vitrectomy for severe vitreous hemorrage in diabetic retinopathy: DRVS report № 5. //Arch.Ophthalmol. 1990. — Vol. 108. — P.958−964.
- DRSRG. Fundus photohgraphic risk factors for progression diabetic retinopathy. //Ophthalmology. 1991. — Vol. 98. — № 5.- supplement.
- Early photocoagulation for diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group //Ophthalmology. — 1991. — Vol. 98. — P.741.-supplement.
- Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. The Diabetic Retinopathy Vitrectomy Study Research Group //Ophthalmology. — 1988. — Vol. 95. — P. 1307−1320.
- Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. -The Diabetic Retinopathy Study Research Group //Arch.Ophthalmol. 1990. — Vol. 108. -P.958−963.
- ETDRS Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic retinopathy study findings Report № 8 // Ophthalmology. 1981. — Vol. 88. — P.583−600.
- Federman J.L., Gouras P., Schubert H., Slusher M.M., Vrabec T.R. Retina and vitreous. // Textbook of ophthalmology. 1994. — Vol. 9 /Ed. by Podos S.M., Yanoff M.- St. Louis: C.V. Mosby.
- Ferrara N., Henzel W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. // Biochem. Biophys. Res. Commun. 1989. — Vol. 161. — P.851−858.
- Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. // Am. J. Physiol. Cell Physiol. 2001. — Vol. 280. -P. 1358−1366.
- Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. // Endocr. Rev. 2004. — Vol. 25. — P.581−611.
- Finlay D., Wilkinson G., Kypta R., et al. Retinal cultures // Methods Cell Biol. -1996.-Vol. 51. P.265−283.
- Fleischman J.A., Swartz M., Dixon J.A. Argon laser endophotocoagulation. An intraoperative trans-pars plana technique. //Arch. Ophthalmol. 1981. — Vol. 99. — P.1610−1613.
- Francois I., Cambic E., De Laev I. Photocoagulation in diabetic retinopathy focal treatment or partial retinal ablation. //Arch.Ophthalmol. 1975. — Vol. 7(2). -P.183−189.
- Frederick L.F. The results of twenty years of reseach in treatment of diabetic retinopathy. //New dimentions in retina. Chicago, Illinois. — 1993. — P. 11−13.
- Freyler H., Klemen U., Prscavec F., Egerer I. Treatment of advanced proliferative diabetic retinopathy. Pothocoagulation of vitrectomy. //Metab. Pediatr. Ophthalmol. 1980. — Vol. 4. — P. 129−132.
- Gao G., Li Y., Zhang D., Gee S., Crosson C., Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. // FEBS Lett. -2001. Vol. 489(2−3). — P.270−276.
- Garcia C.A., Ruiz R.S. Ocular complications of diabetes.// Clin. Symp. -1992. Vol. 44(1). — P.22−32.
- Gaudreault J., Fei D., Rusit J. et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. // Invest. Ophthalmol. Vis. Sci. 2005. — Vol. 46. — P.726−733.
- Goldberg M., Herbst R. Acute complications of argon laser photocoagulation. //Arch.Ophthalmol. 1973. — Vol. 89. — P.311−316.
- Gragoudas E., Adamis A., Cunningham E. T. et al. Pegaptanib for neovascular age-related macular degeneration. // N. Engl. J. Med. — 2004. -Vol. 351.-P.2805−2816.
- Grant M., Russel В., Fitzgerald C., Merimee T. J. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. // Diabetes. 1986. -Vol.35. — P.416−420.
- Grisanti S., Biester S., Peters S. et al. Intracameral bevacizumab for iris rubeosis. // Am. J. Ophthalmol. 2006. — Vol. 142(1). — P.158−160.
- Grunwald J. E., Haripsarad S. M., DuPont J. et al. Foveolar choroidal blood flow in age-related macular degeneration. // Invest. Ophthalmol. Vis. Sci. 1998. -Vol. 39. -P.385−390.
- Hoff A., Hammerle H., Schlosshauer B. Organotypic culture system of chicken retina // Brain Res. Brain Res. Protoc. 1999. — Vol. 4(3). — P.237−248.
- Holekamp N.M., Bouck N., Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. // Am. J. Ophthalmol. 2002. — Vol. 134(2). -P. 200−207.
- Houenou L., D’Costa A., Turgeon V., Enyadike C., Alberti E., Becerra S. Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons. //J. Сотр. Neurol. 1999. — Vol. 412. — P.506−514.
- Husain D, Ambati B, Adamis AP. Mechanisms of age-related macular degeneration. // Ophthalmol. Clin. North. Am. 2002. — Vol. 15(1). — P.87−91.
- Inan U.U., Avei В., Kusbeci T. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rat eyes. // Invest. Ophthalmol. Vis. Sci. 2007. — Vol. 48. — P. 1773−1781.
- Ito Y., Sodeyama Т., Mori K., Anzail K., Takita Y., Imai D., Shibuya M., Yoneya S., Moshfeghi DM, Peyman G.A. Comparative Study of Visible and1. frared Light in Transpupillary Thermotherapy. // Invest
- Ophthalmol. Vis. Sci. 2002. — Vol. 43. — P. 4419−4424.
- Jaworowski A., Fang Z., Khong T.F., Augusteyn R.C. Protein synthesis and secretion by cultured pigment epithelia // Biochim. Biophys. Acta. 1995. — Vol. 1245(1).-P.121−129.
- Joussen A.M., Murata Т., Tsujikawa A. et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. // Am. J. Pathol. 2001. -Vol. 158.-P.147−152.
- Kahook M.Y., Schuman J.S., Noecker R.J. Needle bleb revision of encapsulated filtering bleb with bevacizumab.// Ophthal. Surg. Lasers. 2006. -Vol. 37. -P.148−150.
- Karakousis P.C., John S.K., Behling K.C. et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. // Mol. Vis. 2001. — Vol. 7. — P.154−163.
- KatsuraY., Okano Т., Noritake M., et al. Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. // Diabetes Care. 1998. — Vol. 21. — P.1759−1763.
- Khan S., Beer P.M., Falk N. et al. // 24-th Annual ASRS Meeting/ 6-th Annual EVRS Meeting. Cannes, 2006. — P.80−85.
- Kim I., Ryan A.M., Rohan R. et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. // Invest. Ophthalmol. Vis. Sci. 1999. -Vol. 40.-P.2115−2121.
- Kim J.E., Perkins S.L., Schwiesow Т., Connor T.B., Han D.P. Transpupillary thermotherapy of occult choroidal neovascularization in age-relatedmacular degeneration.//Seminars in Ophthalmology. 2001. — Vol.16(2). -P.86−89.
- Klagsbrun M., D’Amore P.A. Regulators of angiogenesis. //Ann. Rev. Physiol. 1991.-Vol. 53.-P.217−239.
- Klaver C.C., Wolfs R.C., Vingerling J.R., Hofman A. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. // Arch. Ophthalmol. 1998. — Vol. 116(5). — P.653−658.
- Klein R. Diabetic retinopathy. // Ann. Rev. Publ. Health. 1996. — Vol. 17. — P.137−158.
- Klein R., Klein B.E.K., Lee K.E., et al. Changes in visual acuity in a population over a 10-year period. The Beaver Dam Study. // Ophthalmology. -2001.-Vol. 108. P.1757−1766.
- Kojima K., Susuki M., Harada T. et al. Xenon photocoagulation in juvenile diabetic retinopathy (author's transl.). // Acta. Soc. Ophthalmol. Jap. 1978. — Vol. 82(6). — P.457−463.
- Kong Y.C., Han M., Zhao K.X. Expression of vascular endothelial growth factor and pigment epithelium derived factor in mouse oxygen-induced retinopathy and its significance. // Zhonghua Yan Ke Za Zhi. 2008. — Vol. 44(8). — P.734−740.
- Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. // Clin. Ther. 2007. — Vol. 29(9). -P.1850−1861.
- Krzystolik M.G., Afshari M.A., Adamis A.P. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. // Arch. Ophthalmol. 2002. — Vol. 120. — P.338−346.
- Landers M.B., Trese M.T., Stefansson E., Bessler M. Argon laser intraocular photocoagulation. //Am. Acad. Ophthalmol. 1982. — Vol. 89(7). -P.785−788.
- Lanzetta P., Pirracchio A., Bandello F. Optical coherence tomography of subfoveal choroidal neovascularization treated with transpupillary thermotherapy. // Semin. Ophthalmol. 2001. — Vol. 16(2). — P.97−100.
- L’Esperance F. Ophthalmic lasers photocoagulation, photoradiation and surgery. // St. Louis: C.V. Mosby. 1983. -P.250−256.
- Lieth E., Gardner Т., Barber A. J., Antonetti D. Retinal neurodegeneration: early pathology in diabetes.//Clin. Exp. Ophthalmol. 2000. — Vol. 28 (1). — P.3−8.
- Little H.L. Preventing complications in argon laser retinal photocoagulation. //Symposium on light coagulation. Doc. Ophthalmol. Proc. Ser. /Ed. by Francois J. 1972. — Vol. 1. — P.87−95.
- Little H.L. Treatment' of proliferative diabetic retinopathy. //Ophthalmology. 1985. — Vol. 92(2). — P.279−283.
- Little H.L., Zweng H.C., Jack R.L. Vassiliadis A. Techniques of argon laser photocoagulation in the treatment of diabetic disc new vessels. //Am. J. Ophthalmol. 1976. — Vol. 82. — P.675−683.
- Little H.L., Zweng H.C. Complications in argon laser photocoagulation. //Trans. Рас. Coast. Ophthalmol. Soc. 1971. — Vol. 53. — P. l 15−120.
- Lodovichi C., Berardi N., Pizzorusso T et al. Effects of neurotrophins on cortical plasticity: Same or different? // J.Neurosci. 2000. — Vol.20(6). — P.2155−2165.
- Machemer R. A new concept for vitreous surgery: II. Surgical technique and complications. //Am. J. Ophthalmol. 1972. — Vol. 74(6). — P.1022−1033.
- Machemer R. A new concept for vitreous surgery: 1П. Indications and results. //Am. J. Ophthalmol. 1972. — Vol. 74(6). — P.1034−1056.
- Machemer R. A new concept for vitreous surgery: IV. Two instrument techniques in pars plana vitrectomy. //Arch. Ophthalmol. 1974. — Vol. 92. -P.407−412.
- Machemer R., Buettner H., Norton E. Vitrectomy: A pars plana approach. //Trans. Am. Acad. Ophthalmol.Otolaringol. 1971. — Vol. 75. — P.813−820.
- Macular Photocoagulation Study Group. Argon lazer photocoagulation for neovascular maculopaty after five years: results from randomized clinical trials. // Arch. Ophthalmol. 1991.-Vol. 109(9).-P.l 109−1114.
- Macular Photocoagulation Study Group. Occult choroidal neovasculararization. Influence on visual outcome in patients with AMD. // Arch. Ophthalmol. 1996. — Vol. 114(93). — P.400−412.
- Mainster M.A. Decreasing retinal photocoagulation damage: principles and techniques. // Semin. Ophthalmol. 1999. — Vol. 14(4). — P.200−209.
- Marciniak K., Butwicka A., Nowak J.Z. PEDF: an endogenousfactor displaying potent neuroprotective, neurotrophic and antiangiogenic activity. // Postepy. Hig. Med. Dosw. 2006. — Vol. 60. — P.387−396.
- Marneros A.G., Fan J., Yokoyama Y. et al. Vascular endothelial growth factor expression in retinal pigment epithelium is essential for choriocapillarisdevelopment and vision function. // Am. J. Pathol. 2005. — Vol. 167.-P.1451−1459.
- Mason J.O., Albert M.A. et al. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. // Retina. 2006. — Vol. 26. -P.356−357.
- McAvoyJ.W., Chamberlain C.G. Growth factors in the eye. // Prog. Growth Factor Res. 1990. — Vol. 2. — P.29−43.
- Matsuyama K., Ogata N., Matsuoka M. et al. Relationship between pigment epithelium-derived factor (PEDF) and retinal function in patients with diabetic retinopathy. // Mol. Vis. 2008. — Vol. 14. — P.992−996.
- Merimee T.J. Diabetic retinopathy: A synthesis of perspectives. //N. Eng. J. Med. 1990. — Vol. 322. — P.978−983.
- Miller J.W., Adamis A.P., Shima D.T. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. // Am. J. Pathol. 1994. — Vol. 145. -P.574−584.
- Mocanu С. Mechanism of angiogenesis. Ocular involvement. // Ophthalmologia. 2003. — Vol. 59(4). — P.3−8.
- Mori K., Duh E., Gehlbach P., et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. // J. Cell. Physiol. 2001. — Vol. 188. — P.253−263.
- Mori K., Gehlbach P., Ando A., McVey D., Wei L., Campochiaro P.A. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. // Invest. Ophthalmol. Vis. Sci. 2002. — Vol. 43(7). — P.2428−2434.
- Mylan R., Van-NewKirk J. The prevalence of age-related maculopathy. // Arch. Ophthalmol. 1988. — Vol. 106(2). — P.192−198.
- Nguyen Q.D., Shah S., Tatlipinar S. et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. // Br. J. Ophthalmol. -2005.-Vol. 89. P.1368−1370.
- Nishijima K., Yin-Shan N., Zhog L. et al. Vascular endothelial growth factor-A is a survival factor for retinal neuros and a critical neuroprotectant during the adaptive response to ischemic injury. // Am. J. Pathol. 2007. — Vol. 171. -P.53−67.
- Ogata N., Imaizumi M., Miyashiro M., Arichi M., Matsuoka M., Ando A., Matsumura M. Low levels of pigment epithelium-derived factor in highly myopic eyes with chorioretinal atrophy. // Am. J. Ophthalmol. 2005. — Vol. 140(5). -P.937−939.
- Ogata N., Matsuoka M., Imaizumi M., Arichi M., Matsumura M. Decrease of pigment epithelium-derived factor in aqueous humor with increasing age. // Am. J. Ophthalmol. 2004. — Vol. 137(5). — P. 935−936.
- Ogata N., Matsuoka M., Imaizumi M., Arichi M., Matsumura M. Decreased level of pigment epithelium-derived factor in eyes with neroretinal dystrophic diseases. // Am. J. Ophthalmol. 2004. — Vol. 137(6). — P. l 129−1130.
- Ogata N., Nishikawa M., Nishimura Т., Mitsuma Y., Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. // Am. J. Ophthalmol. 2002. — Vol. 134(3). — P.348−353.
- Ogata N., Wada M., Otsuji Т., Jo N., Tombran-Tink J., Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. // Invest. Ophthalmol. Vis. Sci. 2002. -Vol. 43(4).-P.l 168−1175.
- Okun E., Cibic P. The role of photocoagulation in the thara of proliferative diabetic retinopathy. //Arch. Ophthalmol. 1966. — Vol. 75. — P.337−352.
- O’Malley C., Heintz R. Vitrectomy via the pars plana: A new instrument system. //Trans. Рос. Coast Ophthalmol. Soc. 1972. — Vol. 53. — P.121−137.
- Oosterhuis J.A., Journee-de Korver H.G., Kakebeeke-Kemme H. M, Transpupillary thermotherapy in choroidal melanomas. // Arch. Ophthalmol. -1995.-Vol. 113. -P.315−321.
- Oosterhuis J.A., Journee-de Korver H.G., Keunen J.E.E. Transpupillary thermotherapy. Results in 50 patients with choroidal melanoma. // Arch. Ophthalmol. 1998.-Vol. 116. — P. l 57−162.
- O’Reilly M.S., Boehm Т., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. // Cell. 1997. — Vol. 88. — P.277−285.
- O’Reilly M.S., Holmgren S., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. //Cell. 1994. — Vol. 79. -P.315−328.
- Oshima Y., Sakagushi H., Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. // Am. J. Ophthalmol. 2006. — Vol. 142. -P.155−158.
- Pang I.H., Zeng H., Fleenor D.L., Clark A.F. Pigment epithelium-derived factor protects retinal ganglion cells. // BMC Neurosci. 2007. — Vol. 8. — P. l 1−17.
- Paskowitz D.M., Nune G., Yasumura D., et al. BDNF reduces the retinal toxicity of verteporfin photodynamic therapy. // Invest. Ophthalmol. Vis. Sci. -2004. Vol. 45(11). — P.4190−4196.
- Pavan P., Folk J., Weingest T. et al. Diabetic rubeosis and panretinal photocoagulation. //Arch. Ophthalmol. 1983. — Vol. 101(6). — P.882−884.
- Payman G., Dodoch N. Experimental vitrectomy: instrumention and surgical technique. //Arch. Ophthalmol. 1971. — Vol. 86. — P.548−551.
- Payman G.A., Grisolano J.M., Palacio M.N. Intraocular photocoagulation with the argon-krypton laser. //Arch. Ophthalmol. 1980. — Vol. 98. — P.2062−2064.
- Perry W.Y., Christine A.C. Chorioretinal atrophy: Bruch membrane changes and photoreceptor loss. // Ophthalmology. 2002. — Vol. 107. — P. 334 343.
- Peter A. Campochiaro. Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances. // Invest. Ophthalmol. Vis. Sci. 2006. — Vol. 47. — P.462−474.
- Puliafito C.A., Deutsch T.F., Boll J., Eng M., To K. Semiconductor laser endophotocoagulation of the retina. //Arch. Ophthalmol. 1987. — Vol. 5. — P.424−427.
- Qaum Т., Xu Q., Joussen A.M. et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. // Invest. Ophthalmol. Vis. Sci. 2001. — Vol. 42. -P.2408−2413.
- Rehak J., Karhan J. Personal experience in the treatment of proliferative diabetic retinopathy using an argon laser. //Cesk-Oftalmol. 1992. — Dec. — Vol. 48(6). — p.440−446.
- Reichel E., Berrocal A.M., Ip M. Transpupillary thermotherapy of subfoveal macular degeneration. // Ophthalmology. -1999. Vol. 106. — P.1908−1914.
- Rickman D.W. Parvalbumin immunoreactivity is enhanced by brain-derived neurotrophic factor in organotypic cultures of rat retina. // J. Neurobiol. -1999.- Vol. 41(3). P.376−384.
- Rivellese M.J., Baumal C.R. Photodynamic therapy of eye diseases. // J. Ophthalmic Nurs Technol. 2000. — May-Jun. — Vol. 19 (3). — P. 134−141.
- Roberts W.G., Palade G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. // Cancer Res. 1997. — Vol. 57. -P.765−772.
- Rosenfeld P.J., Fung A.E., Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.// Ophthal. Surg. Lasers. 2005. — Vol. 36. -P.336−339.
- Rosenfeld P.J., Moshfeghi A.A., Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.// Ophthal. Surg. Lasers. 2005. -Vol. 36.-P.331−335.
- Roth D.B., Downie A.A., Charles S.T. Visual results after submacular surgery for neovascularization in age-related macular degeneration.// Ophthal. Surg. Lasers. 1997. — Vol. 28(11). — P.920−925.
- Sato J., Kamata A., Matsu M. Clinical studies on maculor changes in diabetic retinopathy. Part I. The classification and maculor changes in diabetic retinopathy. //Acta. Soc. Ophthalmol. Jap. 1981. — Vol. 85(9). — P. 1408−1474.
- Schmidt- Erfurth U., Hasan T. Mechanismus of Action of Photodynamic Therapy with Verteporfin for the Treatment of Age Related Macular Degeneration. // Surv. Ophthalmol. 2000. — Vol. 45. — P. 195- 214.
- Schmidt-Erfurth U., Miller J., Sickenberg M., Bunse A. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. // Graefes Arch. Clin. Exp. Ophthalmol. 1998. — Vol. 236(5). — P.365−374.
- Shields C.L. Transpupillary thermotherapy in the management of choroidal melanoma // Ophthalmology. 1996. — Vol. 103. — P.1642−1650.
- Shields C.L., Shields J.A., Cater J., Transpupillary thermotherapy for choroidal melanoma. Tumor control and visual results in 100 consecutive cases. // Ophthalmology. 1998. — Vol. 105. — P.581−590.
- Shima D.T., Gougos A., Miller J.W. et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. // Invest. Ophthalmol. Vis. Sci. 1996. — Vol. 37. -P.1334−1340.
- Simo R., Carrasco E., Garcia-Ramirez M., Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. // Curr. Diabetes Rev. -2006.-Vol. 2(1). -P.71−98.
- Simorre-Pinatel V., Guerrin M., Chollet P. et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway.// Invest. Ophthalmol. Vis. Sci. 1994. — Vol. 35. — P.3393−3400.
- Sivalingam A., Kenney J., Brown G. C., Benson W. E., Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. //Arch. Ophthalmol. 1990. — Vol. 108. — P.869−872.
- Smiddy W.E. Diode endolaser photocoagulation. //Arch. Ophthalmol. -1992.-Vol. 110.-P.l 172−1174.
- Smith L.E., Wesolowski E. Oxygen-induced retinopathy in the mouse. // Invest. Ophthalmol. Vis. Sci. 1994. — Vol. 35. — P. l01−111.
- Smith W., Assin K.J., Klein R., et al. Risk factors for age-related macular degeneration. Pooled findings from three continents. // Ophthalmology. 2001. -Vol. 108. -P.697−704.
- Spaide R.F., Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. // Retina. 2006. — Vol. 26. — P.275−278.
- Spaide R.F., Laud K., Fine H.F. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. // Retina. 2006. — Vol. 26(4). — P.383−390.
- Steele F.R., Chader G.J., Johnson L.V., Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. // Proc. Natl. Acad. Sci. USA.- 1993. Vol. 90. -P. 1526−30.
- Stellmach V., Crawford S.E., Zhou W., Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. //Proc. Natl. Acad. Sci. USA. 2001. — Vol. 98. — P.2593−2597.
- Stone J., Itin A., Alon T. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia.// J. Neurosci. 1995. — Vol. 15. — P.4738−4747.
- Tanawaki Т., HarashimaN., Becerra S., Chader G., Etcheberrigary R., Schwartz J. Pigment epithelium-derived factor protects cultured cerebellar granule cells against glutamate-induced neurotoxicity. // J. Neurochem. 1997. — Vol. 68. — P.26−32.
- Taniwki Т., Harashima N., Chader G., Schwartz J. Pigment epithelium-derived factor is a survival factor for cerebellar granule cells in culture. // J. Neurochem. 1995. — Vol. 64. — P.2509−2517.
- Thieme H., Aiello L.P., Takagi H. et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells.// Diabetes. 1995. — Vol. 44. — P.98−103.
- Thomas E. L. // 24-th Annual ASRS Meeting/ 6-th Annual EVRS Meeting. Cannes, 2006. — P.83−88.
- Thompson J.T. Retinal pigment epithelial tear after transpupillary thermotherapy for choroidal neovascularization. // Am. J. Ophthalmol. 2001. — Vol. 131. — P.662−664.
- Tobe Т., Okamoto N., Vinores M.A. et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. // Invest. Ophthalmol. Vis. Sci. -1998. Vol. 39. — P.180−188.
- Tolentino M.J., Miller J.W., Gragoudas E.S. et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. // Arch. Ophthalmol. 1996. — Vol. 114. -P.964−970.
- Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function and signaling. // Front. Biosci. -2005.-Vol. 10. -P.2131−49.
- Tombran-Tink J., Chader G.J., Johnson L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. // Exp. Eye Res. 1991. -Vol. 53.-P.411−414.
- Tombran-Tink J., Johnson L.V. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. // Invest. Ophthalmol. Vis. Sci. 1989.-Vol. 30.-P.1700−1707.
- Tombran-Tink J., Shivaram S., Chader G., Johnson L., Bok D. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. // J. Neurosci. 1995. — Vol. 15. — P.4992−5003.
- Tong J.P., Yao Y.F. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. //Clin. Biochem. 2006. — Vol. 39(3). — P.267−276.
- Van Wijngaarden P., Coster D. J., Williams K. A. Inhibitors of ocular neovascularization: promises and potential problems. // J. A. M. A. 2005. -Vol. 293.-P. 1509−1513.
- Verma D. Pathogenesis of diabetic retinopathy-the missing link? // Med. Hypotheses. 1993. — Vol. 41(3). — P.205−210.
- Williams D.F., Bennett S.R. et al. // 24-th Annual ASRS Meeting/ 6-th Annual EVRS Meeting. Cannes, 2006. — P.82−87.
- Williams R.A., Brady B.L., Thomas R.J. The psychosocialimpact of macular degeneration. // Arch. Ophthalmol. 1998. — Vol. 116(4). — P.514−520.
- Wong W.T., Rex T.S., Auricchio A., Maguire A.M., Chung D., Tang W., Bennett J. Effect of over-expression of pigment epithelium derived factor (PEDF) on developing retinal vasculature in the mouse. //Mol. Vis. 2004. — Vol. 10. — P.837−844.
- Wu Y.Q., Notario V., Chader G.J., Becerra S.P. Identification of Pigment Epithelium-Derived Factor in the Interphotoreceptor Matrix of Bovine Eyes. //Protein Expr. Purif. 1995. — Vol. 6. — P. 447156.
- Yoshida A., Yoshida S., Khalil A.D., et al. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. // Invest. Ophthalmol. Vis. Sci. 1998. — Vol. 39. — P.1097—1106.
- Zarbin M.A. Current concepts in the pathogenesis of age-related macular degeneration. // Arch. Ophthalmol. 2004. — Vol. 122. — P.598−614.
- Zweng H.C., Little H.L., Hammond A.H. Complications of argon laser photocoagulation in diabetic retinopathy. //Trans. Am. Acad. Ophthalmol. 1974. -Vol. 78. — P.195−198.
- Zweng H.C., Little H.L., Peabody R.R. Laserphotocoagulation of macular lesions. // Trans. Am. Acad. Ophthal. Otolaryngol. -1968. Vol. 72(3). — P.377−388.